Paris (ots/PRNewswire) - Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnated Heparin (UFH). The ExTRACT-TIMI ...
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based ...
St. Peter Port, Guernsey, Channel Islands (ots/PRNewswire) - In the news release, European Capital (Nasdaq: ACAS) Increases Q3 Dividend 30% to euro 0.13, issued earlier today by European Capital Limited over PR Newswire, was incorrectly transmitted by PR Newswire, the complete, corrected release follows: ST. PETER PORT, Guernsey, Channel Islands, August 22 /PRNewswire/ -- European Capital Increases Q3 ...
St. Peter Port, Guernsey, Channel Islands (ots/PRNewswire) - - Reports euro 0.18 NOI and euro 0.21 Realised Earnings in Q2 2007 European Capital Limited ("European Capital") (LSE: ECAS) announced today its third quarter 2007 dividend and its results for the second quarter of 2007. THIRD QUARTER 2007 DIVIDEND DECLARATION European Capital's Board of Directors has declared a third quarter 2007 dividend of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 20.08.2007 »First data from 25 patients reveals statistically significant viral load reduction and very good safety profile »Data opens door for therapeutic ...
. Total Group revenues increased to EUR 562.5 million . Profit after tax increased to over EUR 18 million . Full-year 2007 profit forecast raised ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/finances Schrobenhausen, August 14, 2007 - (euro adhoc) - BAUER Aktiengesellschaft made effective use of highly positive market conditions to improve ...
Lakewood, Colorado (ots/PRNewswire) - NewWest Gold Corporation (TSX:NWG) ("NewWest"), one of the largest holders of precious metals mineral rights projects in Nevada's established gold trends, today announced its results for the second quarter ended June 30, 2007. Second Quarter Summary - NewWest received its first National Instrument 43-101(NI 43-101) ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine ...
Tip announcement for financial statements transmitted by euro adhoc. The issuer is responsible for the content of this announcement. The financial statement is available: in the internet at: http://www.schering.de/scripts/en/40_ir/2007/fin_rep/070808_q12.php?n=ird&c1=reports_financial in the internet on: ...
San Diego (ots/PRNewswire) - Revenues US$2.33 Billion, Diluted EPS US$0.47 Pro Forma Revenues US$2.33 Billion, Diluted EPS US$0.55 Financial Guidance Increased for Fiscal 2007 QUALCOMM Incorporated (Nasdaq: QCOM) today announced record results for the third quarter of fiscal 2007 ended July 1, 2007. Total QUALCOMM (GAAP) Third Quarter Results Total QUALCOMM ...
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival of Previously Untreated Patients Beyond One Year Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the first-line use of Avastin in the ...
World Glaucoma Association (WGA)
Singapore (ots/PRNewswire) - Today, leading experts from the World Glaucoma Association (WGA) launched the group's first consensus on intraocular pressure (IOP). The panel recognized that elevated IOP is the leading risk factor for glaucoma progression and accurate measurement of IOP plays a key role in assessing glaucoma risk and disease management. The panel's ...
Rousset, France (ots/PRNewswire) - - Based on the AT91SO100 chip, the Three New Devices Offer Extensive Flexibility and Security for POS, PIN Pads and Health Card Readers Applications Atmel(R) Corporation (Nasdaq: ATML) announced today the addition of three new members of its AT91SO family for high security systems. These devices are fully compatible with ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, ...
Cork, Ireland (ots/PRNewswire) - - Data Published in The Lancet on TMC125, an Investigational NNRTI from Tibotec TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, ...
Cork, Ireland (ots/PRNewswire) - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults(i) taking Prezista(R) (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral ...
Indianapolis (ots/PRNewswire) - - Daily dosing option is first prescription oral treatment to offer uninterrupted management of erectile dysfunction in select men Lilly (NYSE: LLY) announced today that the European Commission has granted marketing authorization for Cialis(R) (tadalafil)(1) 2.5 mg and 5 ...
San Jose, California (ots/PRNewswire) - - 64- and 48-pin Flash Microcontrollers with USB OTG Atmel(R) Corporation (Nasdaq: ATML) introduced today a second family based on the AVR(R)32 UC core, its 32-bit Flash microcontroller with DSP extensions. Developed for low power PC-centric applications, the AVR32 UC3B Series of MCUs has Full-Speed (12 Mbps) USB 2.0 with On-The-Go (OTG) capability. On-chip SRAM ranges ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
Malvern, Pennsylvania (ots/PRNewswire) - Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution (Myobloc(R)) recently presented at the 11th International Congress of The Movement Disorders Society in ...
Copenhagen, Denmark (ots/PRNewswire) - - Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Combination With CHOP as Front Line Treatment of Follicular NHL. Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular ...
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
Anti-Tumor Necrosis Factor (TNF) Therapy in Inadequately Responding Rheumatoid Arthritis Patients Barcelona (ots) - According to a new study, it is possible to safely switch directly to ORENCIA® from anti-TNF therapy in rheumatoid arthritis patients who have had an inadequate response to anti-TNF therapy. The results were announced today by Bristol-Myers ...
Chicago, Illinois (ots/PRNewswire) - - Only First-line Treatment to Demonstrate Extended Survival in Over a Decade Avastin (bevacizumab), significantly improves the time patients with advanced non-small cell lung cancer (NSCLC) live without their disease advancing ("progression free survival") when added to cisplatin/gemcitabine chemotherapy, compared with ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that it has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending a marketing authorisation be granted for MIRCERA for the treatment of anaemia associated with chronic kidney disease. MIRCERA is ...
Milan, Italy and Stockholm, Sweden (ots/PRNewswire) - - Three-Quarters of Women Were Not Told Their Risk of Recurrence - Older, Less Educated Women or Those Without Internet Access are Particularly Uninvolved and Uninformed - New Tools, Better Communication Between Health Care Professionals and ...
RUEIL- MALMAISON, France, May 23 (ots/PRNewswire) - - Innovative, First-in-Class Medicine Provides New Option for Europeans With Debilitating Disease Bristol-Myers Squibb (NYSE: BMY) announced today the European Commission has granted an approval for ORENCIA(R) (abatacept) for the treatment of rheumatoid ...
Vienna, Austria (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced new data that showed that, in moderate to severe plaque psoriasis patients, ENBREL(R) (etanercept) reduced the severity of nail psoriasis by more than 28 percent at 12 weeks and reduced the signs and ...